T1	Participants 32 78	children with systemic ventricular dysfunction
T2	Participants 199 218	adults and children
T3	Participants 441 632	changes in plasma levels of b-type natriuretic peptide (BNP) in a population of children with systemic ventricular dysfunction and symptomatic heart failure treated with carvedilol or placebo
T4	Participants 690 735	Pediatric Carvedilol Trial (PCT) participants
T5	Participants 1098 1130	children treated with carvedilol
T6	Participants 1354 1370	carvedilol group
